Global Tamiflu (Oseltamivir Phosphate) Market, by Drug Type (Branded and Generic), by Dosage Form (Capsules and Suspension), by Indication (Influenza A, Influenza B, and Swine Flu (H1N1 Influenza A)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 889.2 Million in 2022 and is expected to exhibit a CAGR of 1.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The following is the treatment regimen which is followed for the treatment of influenza A, influenza B, and others. For instance, according to the Center for Disease Control and Prevention (CDC), the below is the treatment regimen mentioned in detail for the treatment of influenza
Global Tamiflu (Oseltamivir Phosphate) Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus disease (COVID-19) pandemic is expected to hamper growth of the global Tamiflu (oseltamivir phosphate) market over the forecast period. The coronavirus cases are not increasing exponentially across the globe. For instance, according to the World Health Organization, as of December 18, 2022, globally, 649 million confirmed cases of COVID-19 and 6.6 million deaths due to COVID-19 were reported.
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.
Global Tamiflu (Oseltamivir Phosphate) Market: Key Developments
In December 2022, Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company, a part of Blue Cross Association, have added the oseltamivir phosphate (capsule 30 mg, 45 mg, 75 mg) and oral suspension and TAMIFLU oral capsule (30 mg, 45 mg and 75 mg) & oral suspension in their plan list. Oseltamivir phosphate is included in Tier 1 or 1b, while Tamiflu is included in Tier 3 of the plan. Tier 1 or 1b mean drugs with a low cost share and Tier 3 means Drugs with a higher cost share than Tier 2.
Browse 29 Market Data Tables and 22 Figures spread through 180 Pages and in-depth TOC on “by Drug Type (Branded and Generic), by Dosage Form (Capsules and Suspension), by Indication (Influenza A, Influenza B, and Swine Flu (H1N1 Influenza A)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Tamiflu (Oseltamivir Phosphate) Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients